PEDS ONCOLOGY
ACUTE LYMPHOCYTIC LEUKEMIA
- Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia (Children's Oncology Group, AALL03N1)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Intensified Methotrexate, Nelarabine (Compound 506U78; IND 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (Children's Oncology Group, AALL0434)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia: Randomization of Highest Risk Infants to Intensive Chemotherapy FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSc#617807) (Children's Oncology Group, AALL0631)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (Children’s Oncology Group, AALL08B1)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (Children’s Oncology Group, AALL0932)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
ACUTE MYELOGENIC LEUKEMIA
ACUTE PROMYELOCYTIC LEUKEMIA
- Risk Adapted Treatment of Newly Disgnosed Childhood Acute Promyelocytic leukemia (APL) using Arsenic Trioxide (Trisenox® IND#103,331) during Consolidation(Children's Oncology Group, AAML0631)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
CENTRAL NERVOUS SYSTEM
- A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial (Children's Oncology Group, ACNS0331)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients (Children's Oncology Group, ACNS0332)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months old with Intensive induction Chemotherapy with Methotrexate followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate (Children's Oncology Group, ACNS0334)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
EWING SARCOMA
- European Ewing Tumor Working Initiative of National Groups, Ewing Tumor Studies 1999 (Euro-E.W.I.N.G.99) (Children's Oncology Group, AEWS0331)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
GERM CELL TUMORS
- A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors Susp to Low Risk (Children's Oncology Group, AGCT0132)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
HODGKIN
- Tissue Banking in Hodgkin Disease (Children’s Oncology Group, AHOD04B1)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- A Non-Randomized Phase III Study of response Adapted Therapy for the Treatment of Children with Newly-Diagnosed High Risk Hodgkin Lymphoma (Children's Oncology Group, AHOD0831)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
LYMPHOBLASTIC LYMPHOMA
NEUROBLASTOMA
- Phase III Randomized Study of Chimeric Antibody 14.18 (Ch 14.18) in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Rescue (Children's Oncology Group, ANBL0032)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Response-and Biology-Based Therapy for Intermediate-Risk Neuroblastoma (Children's Oncology Group, ANBL0531)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High Risk Neuroblastoma (Children's Oncology Group, ANBL0532
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
NEUTROPENIA
- Severe Chronic Neutropenia International Registry (SCN)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
OSTEOSARCOMA
RENAL
- National Wilms Tumor Late Effects Study (Children's Oncology Group, 4941 LE)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Treatment of High Risk Renal Tumors (Children's Oncology Group, AREN0321)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Renal Tumors Classification, Biology and Banking Study (Children's Oncology Group, AREN03B2)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor (Children's Oncology Group, AREN0532)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors (Children's Oncology Group, AREN0533)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor: A Groupwide Phase III Study (Children's Oncology Group AREN0534)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
RHABDOMYOSARCOMA
- Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosacroma (Children's Oncology Group ARST0331)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Risk-Based Treatment for Non-Rhabdomyosacroma Soft Tissue (NRSTS) in Patients Under 30 Years of Age (Children's Oncology Group, ARST0332)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for patients with Intermediate-Risk Rhabdomyosarcoma (RMS) (Children's Oncology Group) Susp to Subset 1 (ARST0531)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
BIOLOGY
- A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (Children's Oncology Group, 9902)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Classification of Acute Lymphoblastic Leukemia (Children's Oncology Group, AALL03B1)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Neuroblastoma Biology Studies: (Children's Oncology Group, ANBL00B1)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
DEVELOPMENTAL
- Safety and efficacy of Varicella Zoster Immune Globulin (Human) (VariZIG™) in Patients At-Risk of Varicella Infection (Cangene Corporation) (VZ-009)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
- Erwinase Master Treatment Protocol (EUSA Pharma, Inc.)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
REGISTRY
- Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) (Children's Oncology Group ACCRN07)
Contact Dawn Borgerson, MSN, RN, CCRP at 419-291-9525 or Julie Moon RN, OCN at 419-291-9540
SURVIVORSHIP
- Physical Activity, Quality of Life & Fatigue in Childhood Cancer Survivors
Contact Liz Musolf MSN, CPNP, CPON at 419-291-9500 or Dawn Borgerson, MSN, RN, CCRP at 419-291-9525
Page 1 of 4
9/12/2018